Onconic Therapeutics unveiled OCN-501, a first-in-class candidate given with GLP-1 obesity drugs to preserve muscle, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results